FTY720 + Oral Corticosteroid

Phase 2Withdrawn
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Conditions

Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Trial Timeline

Nov 1, 2013 → Oct 1, 2014

About FTY720 + Oral Corticosteroid

FTY720 + Oral Corticosteroid is a phase 2 stage product being developed by Novartis for Acute Noninfectious Posterior, Intermediate, or Pan Uveitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01791192. Target conditions include Acute Noninfectious Posterior, Intermediate, or Pan Uveitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01791192Phase 2Withdrawn

Competing Products

20 competing products in Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

See all competitors